日本語 
Eisai Co., Ltd. and Nuvation Bio Inc. have pushed taletrectinib into the next stage in Europe. The European Medicines Agency has validated the application. That basically means the file is…
Doctors Prime Secures ¥420M Debt Financing from Banks
Doctors Prime Co., Ltd. has completed its Series A round with loans…
Ubie Enhances AI Capabilities Through Mayo Clinic Platform_Accelerate Program
Ubie Inc. aims to 'use technology to guide people to appropriate medical…
Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics
PHC Holdings Corporation and its subsidiary Ascensia Diabetes Care, a global diabetes…
Eisai seeks FDA approval for LEQEMBI Subcutaneous dose
Eisai Co., Ltd. and Biogen Inc. have started a rolling supplemental Biologics…
MEDIPAL and JCR Ink Global Deal for GM2 Drug JR-479
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced that the two…
Hitachi and Partners build generative AI healthcare platform
Hitachi Systems, Ltd., Kanagawa Prefecture, MedMirai Co., Ltd., and the University of…
Eisai’s Tazemetostat Approved as Orphan Drug in Japan
Eisai Co., Ltd. announced that it has received orphan drug designation for…
Top 10 Tech-Driven Solutions Tackling Japan’s Aging Population
Japan is known for its resilience and innovation. Its cultural values also…
English